Latest Medicare News news from across the web.
With the federal Medicaid work requirements looming in January, Democrats are considering state legislation to call out big companies that employ workers enrolled in the safety net health program. Business giants such as Amazon and Walmart said the figures are misleading.
Read full article →The FDA now treats continuous, real-time data sharing as a regulatory direction of travel rather than a theoretical future. The neurology field should pay close attention. The post The Measurement Problem Behind Two Decades of Neurology Trial Failures appeared first on MedCity News .
Read full article →You cannot secure what you cannot see, and right now, healthcare organizations are accumulating hidden cyber liabilities with every keystroke. The post Off the Radar: How Unapproved AI Is Complicating Healthcare Cyber Risk appeared first on MedCity News .
Read full article →[Sponsored] On July 22, a webinar sponsored by Verato will spotlight perspectives of executives from Scan Health Plan and the Alliance of Community Health Plans. The post Payers Who Improve Data Quality Will Define the Next Era of Health Plan Performance appeared first on MedCity News .
Read full article →Fairview Health Services turned a $315 million annual loss into a nearly $600 million turnaround in just two years. At the AHA Leadership Summit, CEO James Hereford broke down the strategy behind the comeback, from workforce redesign to frontline-driven process fixes. The post How Fairview Health Services Turned Around a $315M Loss appeared first on MedCity News .
Read full article →The Coalition Against Surprise Medical Billing launched a campaign opposing the No Surprises Act Enforcement Act, arguing it would worsen IDR process abuse. The post Coalition Urges Policymakers to Reject No Surprises Act Enforcement Bill appeared first on MedCity News .
Read full article →Spero Therapeutics enters immunology with an antibody licensed from Innovent Biologics. The lead indication is a rare autoimmune condition where Spero aims to offer advantages over the Amgen drug that is currently the only approved treatment. The post After Antibiotic Approval, Spero Pivots to Immunology Aiming to Rival an Amgen Asset appeared first on MedCity News .
Read full article →